Drug Profile


Alternative Names: BAYQ 6256; Breelib; Ciloprost; E-1030; Endoprost; Ilocit; Iloderm; Ilomedin; Ilomedine; Iloprost inhalation solution; Iloprost power 15 (Ventavis®) - Actelion; Iloprost trometamol; Isoiloprost; SH-401; Ventavis; VR-876 - Vectura; ZK-36375

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Bayer HealthCare Pharmaceuticals
  • Class Alkynes; Anti-ischaemics; Antiplatelets; Peripheral vasodilators; Prostaglandins; Small molecules
  • Mechanism of Action Prostacyclin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension; Pulmonary arterial hypertension
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Arterial occlusive disorders; Pulmonary arterial hypertension; Raynaud's disease; Thromboangiitis obliterans
  • Discontinued Pulmonary hypertension

Most Recent Events

  • 22 Dec 2016 Bayer completed EU regulatory procedure for VR 876 (breath activated nebuliser)
  • 01 Dec 2016 Bayer completes the IBUKI trial in Pulmonary arterial hypertension in Japan (Inhalation) (NCT01469169)
  • 10 Nov 2016 Launched for Pulmonary arterial hypertension in Poland (Inhalation) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top